









Markets
/
Stocks
/
nasdaq-ctmx
/

CytomX Therapeutics Inc

CTMX

5.670USD

+0.430+8.21%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

935.94MMarket Cap

19.25P/E TTM



CytomX Therapeutics Inc

5.670

+0.430+8.21%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CytomX Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

CytomX Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 6 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CytomX Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

6 / 392

Overall Ranking

78 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

CytomX Therapeutics Inc Highlights

StrengthsRisks

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 159.77% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 19.25, at a high 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 22.43K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.50.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.250

Target Price

+63.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of CytomX Therapeutics Inc is 7.26, ranking 132 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.96M, representing a year-over-year decrease of 82.16%, while its net profit experienced a year-over-year decrease of 348.06%.

Score

Industry at a Glance

Previous score

7.26

Change



Financials

6.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.08

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.66

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.16

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CytomX Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of CytomX Therapeutics Inc is 8.80, ranking 17 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 19.25, which is 26.66% below the recent high of 24.38 and 1946.11% above the recent low of -355.38.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of CytomX Therapeutics Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.50, with a high of 10.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.250

Target Price

+63.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

CytomX Therapeutics Inc

CTMX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of CytomX Therapeutics Inc is 9.30, ranking 21 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.65 and the support level at 4.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.62

Change

1.68

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.060

Neutral

RSI(14)

58.086

Neutral

STOCH(KDJ)(9,3,3)

38.066

Sell

ATR(14)

0.537

High Vlolatility

CCI(14)

-23.699

Neutral

Williams %R

51.908

Neutral

TRIX(12,20)

1.390

Sell

StochRSI(14)

33.666

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.748

Sell

MA10

5.734

Sell

MA20

5.299

Buy

MA50

4.597

Buy

MA100

3.968

Buy

MA200

3.028

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CytomX Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 97.87%, representing a quarter-over-quarter decrease of 2.83%. The largest institutional shareholder is The Vanguard, holding a total of 8.48M shares, representing 5.00% of shares outstanding, with 21.70% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

VR Adviser, LLC

15.56M

+11.39%

Fidelity Management & Research Company LLC

13.07M

+50.92%

Longitude Capital Management Co., LLC

11.54M

Tang Capital Management, LLC

11.07M

Perceptive Advisors LLC

9.68M

The Vanguard Group, Inc.

Star Investors

8.95M

-4.61%

OrbiMed Advisors, LLC

8.46M

Commodore Capital LP

7.69M

Baker Bros. Advisors LP

4.25M

+22.00%

Point72 Asset Management, L.P.

Star Investors

4.07M

-49.68%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CytomX Therapeutics Inc is 4.13, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.